NSE / BSEHealthcare
β‚Ή3027.50+47.45+1.59%
P/E42.4Mkt Capβ‚Ή40.11 K CrEV/EBITDA0.0

GlaxoSmithkline Pharmaceuticals Ltd.

P/E42.4Mkt Capβ‚Ή40.11 K CrEV/EBITDA0.0
Company Profile

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, an oral antibiotic to treat bacterial infections; CobadexCZS to treat mineral and vitamins deficiency states; Flutivate, a skin cream for adults, children, and infants; Tenovate to treat inflammatory and pruritic manifestations of steroid responsive dermatosis; CALPOL to treat mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment of specific bacterial skin infections; BETNOVATE for skin conditions; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin associated with redness and itch. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. The company was incorporated in 1924 and is based in Mumbai, India. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 26 Aug 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
β€”
β€”
EV / Sales
β€”
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
β€”
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–² 8.58% over 1Y
Monthly Returns

Historically, May has averaged the highest return (+6.7%); Jan the lowest (-2.7%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-3.0%Negative MonthJan 2026: -2.97%+7.2%Positive MonthFeb 2026: +7.20%-11.2%Negative MonthMar 2026: -11.15%+2.3%Positive MonthApr 2026: +2.29%-5.4%Negative MonthMay 2026: -5.43%+11.0%Positive MonthJun 2026: +10.97%+8.3%Positive MonthJul 2026: +8.26%+14.1%*Positive MonthAug 2026: +14.10%β€”β€”β€”β€”
2025-12.2%Negative MonthJan 2025: -12.24%+25.2%Positive MonthFeb 2025: +25.21%+16.3%Positive MonthMar 2025: +16.28%+2.9%Positive MonthApr 2025: +2.86%+11.3%Positive MonthMay 2025: +11.34%+2.8%Positive MonthJun 2025: +2.78%-6.7%Negative MonthJul 2025: -6.75%-11.9%Negative MonthAug 2025: -11.86%-4.6%Negative MonthSep 2025: -4.56%-1.2%Neutral MonthOct 2025: -1.22%-2.2%Negative MonthNov 2025: -2.19%-3.7%Negative MonthDec 2025: -3.73%
2024+18.5%Positive MonthJan 2024: +18.47%-3.4%Negative MonthFeb 2024: -3.37%-10.5%Negative MonthMar 2024: -10.54%+7.4%Positive MonthApr 2024: +7.41%+26.0%Positive MonthMay 2024: +26.04%+0.8%Neutral MonthJun 2024: +0.82%+3.0%Positive MonthJul 2024: +3.03%+0.5%Neutral MonthAug 2024: +0.46%+0.3%Neutral MonthSep 2024: +0.34%-1.3%Neutral MonthOct 2024: -1.27%-10.1%Negative MonthNov 2024: -10.08%-7.9%Negative MonthDec 2024: -7.92%
2023-5.5%Negative MonthJan 2023: -5.47%+7.1%Positive MonthFeb 2023: +7.06%-0.8%Neutral MonthMar 2023: -0.79%-6.2%Negative MonthApr 2023: -6.20%+5.1%Positive MonthMay 2023: +5.11%+9.1%Positive MonthJun 2023: +9.07%-1.8%Neutral MonthJul 2023: -1.82%+2.2%Positive MonthAug 2023: +2.15%+8.2%Positive MonthSep 2023: +8.15%-7.9%Negative MonthOct 2023: -7.86%+16.4%Positive MonthNov 2023: +16.35%+14.6%Positive MonthDec 2023: +14.58%
2022-11.3%Negative MonthJan 2022: -11.26%-2.7%Negative MonthFeb 2022: -2.74%+9.4%Positive MonthMar 2022: +9.44%-5.5%Negative MonthApr 2022: -5.54%-3.6%Negative MonthMay 2022: -3.61%-1.0%Neutral MonthJun 2022: -0.95%-6.2%Negative MonthJul 2022: -6.17%+3.7%Positive MonthAug 2022: +3.70%-2.4%Negative MonthSep 2022: -2.40%-3.3%Negative MonthOct 2022: -3.29%-2.9%Negative MonthNov 2022: -2.95%-1.3%Neutral MonthDec 2022: -1.34%
2021β€”β€”β€”β€”β€”-1.8%Neutral MonthJun 2021: -1.85%+7.0%Positive MonthJul 2021: +7.02%-4.8%Negative MonthAug 2021: -4.78%-3.3%Negative MonthSep 2021: -3.27%+1.5%Neutral MonthOct 2021: +1.48%+13.3%Positive MonthNov 2021: +13.29%+3.4%Positive MonthDec 2021: +3.39%
AvgΒ±SD-2.7%Β±11.1%+6.7%Β±10.3%+0.6%Β±10.8%+0.2%Β±5.2%+6.7%Β±11.4%+3.5%Β±4.9%+0.6%Β±5.9%+0.6%Β±7.9%-0.3%Β±4.5%-2.4%Β±3.1%+2.9%Β±10.2%+1.0%Β±7.7%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 1.225x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή3.72 K Crβ–² 9.3%
EBITDA Growthβ€”
Net Profitβ‚Ή919.00 Crβ–² 57.1%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–² 1381.3%
Revenue CAGR 5Y0.0%
EBITDA CAGR 5Y0.0%
Net Profit CAGR 5Y0.0%
NP Growth 1Y57.1%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή3.72 K Crβ€”β‚Ή919.00 Crβ€”β€”β€”9.3%57.1%
Mar 2024β‚Ή3.41 K Crβ€”β‚Ή585.00 Crβ€”β€”β€”5.9%-3.8%
Mar 2023β‚Ή3.22 K Crβ€”β‚Ή608.00 Crβ€”β€”β€”-0.1%-64.0%
Mar 2022β‚Ή3.22 K Crβ€”β‚Ή1.69 K Crβ€”β€”β€”10.2%372.3%
Mar 2021β‚Ή2.92 K Crβ€”β‚Ή358.00 Crβ€”β€”β€”-9.5%225.5%
Mar 2020β‚Ή3.23 K Crβ€”β‚Ή110.00 Crβ€”β€”β€”3.1%-74.1%
Mar 2019β‚Ή3.13 K Crβ€”β‚Ή425.00 Crβ€”β€”β€”8.9%20.7%
Mar 2018β‚Ή2.87 K Crβ€”β‚Ή352.00 Crβ€”β€”β€”-1.1%4.5%
Mar 2017β‚Ή2.90 K Crβ€”β‚Ή337.00 Crβ€”β€”β€”2.7%-10.1%
Mar 2016β‚Ή2.83 K Crβ€”β‚Ή375.00 Crβ€”β€”β€”-14.1%-20.6%

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Dec 2013Mar 2015 15mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales2,5463,2882,8262,9032,8723,1293,2252,9203,2183,2163,4073,7233,767
Total Expenses2,0242,6602,3492,4822,3612,5222,5662,3232,4622,4172,5072,5532,483
EBIT / Operating Profit5226274774215116066585987567999011,1711,284
OPM %20191714181920202325263134
Other Income22714712511869106-24781,402104-20146149
Finance Costs0000016422213
Depreciation & Amortisation20252527384983796866706768
Profit Before Tax7297495765115426643225242,0878358091,2481,362
Tax %313735343536663219272826-
Net Profit / PAT5024723753373524251103581,691608585919997
EPS (β‚Ή)29.6327.8422.1119.8820.7825.116.5021.1199.7935.8834.5154.2558.85
Dividend Payout %84112113758480616142908993100-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
GlaxoSmithkline Pharmaceuticals Ltd.this co.β‚Ή40.11 K Crβ‚Ή3.72 K Cr42.4023.460.009.3%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of GlaxoSmithkline Pharmaceuticals Ltd. and the metrics that matter.

Browse the full Equiscale Academy